Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.71 |
| ▸ | GNRHR | P30968 | 2/20 | 0.65 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.64 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.62 |
| ▸ | APLNR | P35414 | 5/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512254 | 1.00 | PTGS1 (0.71) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1652722 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL22289009 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL5079698 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL1371630 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL16815056 | 0.97 | PTGS1 (0.74) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL11678163 | 0.96 | PTGS1 (0.73) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL29425250 | 0.96 | GNRHR (0.70) | PTGS1GNRHRABCC2C5AR1APLNR | |
| Triptorelin SCHEMBL29459903 | 0.96 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1APLNR | |
| SCHEMBL29373920 | 0.96 | PTGS1 (0.72) | PTGS1GNRHRABCC2C5AR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059668-A1 | THIOHYDROXYPYRIDINE CHELATES | LUMIPHORE, INC. | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059668-A1 | THIOHYDROXYPYRIDINE CHELATES | FTH1, SSB, SLC7A1 | PTGS1 2590/4885GNRHR 846/4885ABCC2 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.